Novartis India to Acquire Pfizer’s BP Drug Brands for ₹1,250 Crore

Pfizer and Enodia Therapeutics partnered in a $500m deal to develop Sec61 inhibitors. Enodia will lead discovery work, while Pfizer handles clinical trials and commercialization. Enodia may receive milestone payments and royalties. The collaboration focuses on Enodia's drug discovery platform targeting harmful proteins.

Johnson & Johnson (JNJ) stock fell 5% despite raising its full-year outlook due to one-time charges, including talc litigation. Q3 2026 revenue grew 5.9%, but reported net earnings dropped 95.9%. Eli Lilly (LLY) and Pfizer (PFE) also saw declines. JNJ's growth came from its Innovative Medicine division, while MedTech lagged. The company secured market authorization for its OTTAVA robotic surgical system and priority review for RYBREVANT FASPRO.

Enodia Therapeutics and Pfizer Inc. agreed to collaborate on developing Sec61-targeting small molecules. Enodia will handle discovery, while Pfizer will manage clinical, manufacturing, and commercial activities post-collaboration. Enodia may receive over $500 million in upfront, milestone, and royalty payments.

Pfizer presented phase 3 trial results showing Litfulo (ritlecitinib) significantly improved facial and total body repigmentation in nonsegmental vitiligo compared to placebo. The trials, TRANQUILLO 2 and TRANQUILLO, also showed reduced disease severity and stabilization. Pfizer plans to submit the data to global regulators, including the FDA and EMA. According to Pfizer, Litfulo addresses the root cause of the disease.

A phase 3 trial of Lyme disease vaccine LB6V (Valneva, Pfizer) found it safe and tolerable in children 5-17. The vaccine, containing six serotypes, aims to prevent Lyme disease by targeting ticks. The study included 3,547 participants, with mild-moderate adverse events similar to placebo. FDA approval could follow if efficacy is confirmed.

The American Hospital Association sued to block a 340B Drug Pricing Program pilot starting January 1, 2027, involving AbbVie (ABBV) and Pfizer. The AHA argues the program doesn't compensate hospitals for added costs. AbbVie's stock is 24.6% overvalued, with a 2.46% dividend yield and 85% payout ratio. Its GF Score is 76, showing strong profitability but concerns over valuation and momentum.